TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33296943

Group type: EXPERIMENTAL
Intervention: BAY 94-9027 prophylaxis (damoctocog alfa pegol)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: BAY 94-9027 prophylaxis
Number of subjects: 80
Study: 35394149

Group type: EXPERIMENTAL
Intervention: Intramyocardial administration of autologous neonatal c-kit+ cardiac-derived progenitor cells (nCPCs)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Randomized, double-blinded administration of nCPCs
Number of subjects: 32
Study: 33619999

Group type: EXPERIMENTAL
Intervention: GI biopsy result of normal mucosa
Number of subjects: 1050105

Group type: EXPERIMENTAL
Intervention: GI biopsy result of non-specific inflammation
Number of subjects: 1050105

Group type: COMPARATOR
Intervention: Control group (individuals without GI biopsy)
Number of subjects: 1050105
Study: 32342703

Group type: EXPERIMENTAL
Intervention: Remote follow-up (RFU)
Number of subjects: 1274

Group type: COMPARATOR
Intervention: Conventional in-office follow-up
Number of subjects: 1274
Study: 34399009

Group type: EXPERIMENTAL
Intervention: Pain ratings provided by a single person (group 3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pain ratings provided by a group of people (group 4)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pain ratings presented to participants (group 1 and 2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no manipulation)
Number of subjects: 0
Study: 34900170

Group type: EXPERIMENTAL
Intervention: Glucantime plus SinaAmpholeish (topical nano-liposomal amphotericin B 0.4%)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Glucantime (intralesional injections)
Number of subjects: 130
Study: 36476743

Group type: EXPERIMENTAL
Intervention: Text + Pictogram HWLs
Number of subjects: 1755

Group type: EXPERIMENTAL
Intervention: Text + Photograph HWLs
Number of subjects: 1755

Group type: EXPERIMENTAL
Intervention: Text-Only HWLs
Number of subjects: 1755

Group type: COMPARATOR
Intervention: DrinkWise control
Number of subjects: 1755

Group type: COMPARATOR
Intervention: No HWL control
Number of subjects: 1755
Study: 33761143

Group type: EXPERIMENTAL
Intervention: 1.91 g of red clover extract (containing 8 mg formononetin and 1.8 mg biochanin A)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 32192539

Group type: EXPERIMENTAL
Intervention: Group PM+/enhanced care as usual (Group PM+/E-CAU)
Number of subjects: 380

Group type: COMPARATOR
Intervention: Enhanced care as usual (E-CAU)
Number of subjects: 380
Study: 32653904

Group type: EXPERIMENTAL
Intervention: AKB‐9778
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Yoda1 (PIEZO1 activator)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: VE‐PTP inhibition
Number of subjects: 0
Study: 35796684

Group type: EXPERIMENTAL
Intervention: Miamo Renewal Peel Serum (ELPA25™) applied three times a week for 8 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Mandelic acid serum (control) applied three times a week for 8 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (control) applied three times a week for 8 weeks
Number of subjects: 30
Study: 33685395

Group type: EXPERIMENTAL
Intervention: Pressure-controlled ventilation volume-guaranteed (PCV-VG)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Volume-controlled ventilation (VCV)
Number of subjects: 80
Study: 35995103

Group type: EXPERIMENTAL
Intervention: Very Low Nicotine Content (VLNC) cigarettes (0.4 mg/g of tobacco)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Normal Nicotine Content (NNC) cigarettes (15.8 mg/g of tobacco)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: E-liquid with low nicotine (0.3%)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: E-liquid with moderate nicotine (1.8%)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: E-liquids available in various flavors (tobacco, fruit, dessert, mint)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: E-liquids available in tobacco flavors
Number of subjects: 50
Study: 33863850

Group type: EXPERIMENTAL
Intervention: MotionWatch 8 (MW8) triaxial actigraphy device
Number of subjects: 321
Study: 33555332

Group type: EXPERIMENTAL
Intervention: Device monitoring and feedback during intervention period
Number of subjects: 97

Group type: COMPARATOR
Intervention: Baseline (no device)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Transition (device monitoring without feedback)
Number of subjects: 97
Study: 32367010

Group type: EXPERIMENTAL
Intervention: CK advertisement
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: CK advertisement with disclaimers
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Scientific information from peer-reviewed literature
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 400
Study: 35172043

Group type: EXPERIMENTAL
Intervention: New tablet, fasted (reference, dosed twice)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: New tablet, 30 minutes after a high-fat meal (test 1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Old tablet, fasted (test 2)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Navtemadlin (overall)
Number of subjects: 30
Study: 32675585

Group type: EXPERIMENTAL
Intervention: Nonoperative treatment
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: VAS pain score at 4 weeks
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: VASratio (VAS pain score at 4 weeks divided by VAS pain score at 2 weeks)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: VASratio above 0.6
Number of subjects: 64
Study: 32912974

Group type: EXPERIMENTAL
Intervention: Metacognitive therapy (MCT) plus usual care (UC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 0
Study: 35276867

Group type: EXPERIMENTAL
Intervention: Hydrogen-rich water (HRW) supplementation
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 33649520

Group type: EXPERIMENTAL
Intervention: rostafuroxin 50 μg
Number of subjects: 279

Group type: COMPARATOR
Intervention: losartan 50 mg
Number of subjects: 279
Study: 35074878

Group type: EXPERIMENTAL
Intervention: High-cash gift group (monthly unconditional cash gift)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Low-cash gift group (nominal monthly unconditional cash gift)
Number of subjects: 1000
Study: 34593725

Group type: EXPERIMENTAL
Intervention: Neoprene knee sleeve (WS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No knee sleeve (NS)
Number of subjects: 20
Study: 35931480

Group type: EXPERIMENTAL
Intervention: Probiotic treatment (PB) with 2 g of PBF1 added to colostrum and 1 g of PBF2 added to milk 3 times per week until weaning
Number of subjects: 232

Group type: COMPARATOR
Intervention: Control group (CTR) receiving no probiotics
Number of subjects: 232
Study: 32271358

Group type: EXPERIMENTAL
Intervention: At least 2-step 2-year progression
Number of subjects: 3868

Group type: EXPERIMENTAL
Intervention: At least 3-step 2-year progression
Number of subjects: 3868

Group type: EXPERIMENTAL
Intervention: Development of neovascular (NV) AMD
Number of subjects: 3868

Group type: EXPERIMENTAL
Intervention: Development of central geographic atrophy (CGA)
Number of subjects: 3868

Group type: EXPERIMENTAL
Intervention: Development of any geographic atrophy (GA)
Number of subjects: 3868

Group type: EXPERIMENTAL
Intervention: At least 2-line BCVA loss
Number of subjects: 3868

Group type: EXPERIMENTAL
Intervention: At least 3-line BCVA loss
Number of subjects: 3868

Group type: EXPERIMENTAL
Intervention: At least 2-step 2-year progression and subsequent development of NV AMD
Number of subjects: 3868

Group type: EXPERIMENTAL
Intervention: At least 2-step 2-year progression and subsequent development of CGA
Number of subjects: 3868
Study: 35674649

Group type: EXPERIMENTAL
Intervention: Individualized Comprehensive Rehabilitation (ICR)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Aquatic Training
Number of subjects: 40
Study: 34003963

Group type: EXPERIMENTAL
Intervention: Brolucizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aflibercept
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All subjects (treatment agnostic)
Number of subjects: 0
Study: 32429069

Group type: EXPERIMENTAL
Intervention: Educational SMS intervention on nutrition and physical activity during pregnancy, one text message per week for eighteen weeks.
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group received SMS about general health topics during pregnancy, one text message per week for eighteen weeks.
Number of subjects: 83
Study: 35832128

Group type: EXPERIMENTAL
Intervention: Continuous care based on the combination of medical care and nursing (Observation Group)
Number of subjects: 96
Study: 34695679

Group type: EXPERIMENTAL
Intervention: Parent-administered early intervention
Number of subjects: 141

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 141
Study: 32468992

Group type: EXPERIMENTAL
Intervention: Fascial Distortion Model (FDM) intervention
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Foam rolling technique
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 90
Study: 35777616

Group type: EXPERIMENTAL
Intervention: Hybrid pegylated liposomal doxorubicin (PLD) hydrochloride injection
Number of subjects: 50

Group type: COMPARATOR
Intervention: Caelyx®
Number of subjects: 50
Study: 34324065

Group type: EXPERIMENTAL
Intervention: Genetically predicted PD-1/PD-L1
Number of subjects: 3301

Group type: EXPERIMENTAL
Intervention: Higher PD-1 levels
Number of subjects: 3301

Group type: EXPERIMENTAL
Intervention: Lower PD-L1 levels
Number of subjects: 3301

Group type: COMPARATOR
Intervention: Genetically predicted PD-L1
Number of subjects: 3301
Study: 32566971

Group type: EXPERIMENTAL
Intervention: Endovascular Aneurysm Repair (EVAR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endovascular options for hostile neck anatomy (fenestrated endografts, chimney grafts, endoanchors)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regular and long-term imaging and clinical surveillance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EVAR technology
Number of subjects: 0
Study: 35926845

Group type: EXPERIMENTAL
Intervention: Adding vibration during varied high-intensity interval training (HIIT) sessions
Number of subjects: 12
Study: 33620499

Group type: EXPERIMENTAL
Intervention: Constructivist teaching method (CTM)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control group (standard education)
Number of subjects: 122
Study: 32525562

Group type: EXPERIMENTAL
Intervention: Ravidasvir (RDV) plus ritonavir-boosted danoprevir (DNVr) and ribavirin (RBV) for 12 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo treatment for 12 weeks
Number of subjects: 16
Study: 35311993

Group type: EXPERIMENTAL
Intervention: Checklist response style
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Thermometer response style
Number of subjects: 31

Group type: COMPARATOR
Intervention: Overall findings
Number of subjects: 31
Study: 32003645

Group type: EXPERIMENTAL
Intervention: Ubiquinol-10 (300 mg/day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 32988951

Group type: EXPERIMENTAL
Intervention: MyndMove neuromodulation therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional therapy (CT)
Number of subjects: 60
Study: 35191232

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 33828260

Group type: EXPERIMENTAL
Intervention: CGA-based interventions
Number of subjects: 142

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 142
Study: 32272458

Group type: EXPERIMENTAL
Intervention: Electrical stimulation at abductor hallucis motor-point with 150 bursts at varying frequencies (8-32 Hz) and stimulation currents (10%, 20%, and 30% higher than m-wave stimulation current)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Electrical stimulation protocols (protocols 1-3) with incremental changes in stimulation frequency
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Validation cohort's test-retest reliability
Number of subjects: 15
Study: 37030179

Group type: EXPERIMENTAL
Intervention: 3D-printed silicone small bowel simulator (8 practice sessions at home)
Number of subjects: 16

Group type: COMPARATOR
Intervention: No hands-on practice (control group)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 3D-printed silicone small bowel simulator (posttest and retention-transfer test)
Number of subjects: 16
Study: 34481768

Group type: EXPERIMENTAL
Intervention: Machine learning-based screening technology using facial photographs
Number of subjects: 2800
Study: 35881397

Group type: EXPERIMENTAL
Intervention: Lyophilized plasma transfusion
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard care with normal saline infusion (control)
Number of subjects: 150
Study: 34266802

Group type: EXPERIMENTAL
Intervention: lidocaine + adrenaline + TXA
Number of subjects: 60

Group type: COMPARATOR
Intervention: lidocaine + adrenaline
Number of subjects: 60
Study: 34098913

Group type: EXPERIMENTAL
Intervention: Collaborative and Stepped Care (CSC) model
Number of subjects: 24

Group type: COMPARATOR
Intervention: Usual mental health care
Number of subjects: 24
Study: 35241369

Group type: EXPERIMENTAL
Intervention: AC plus 0.5 µg of Vit D (Bon One 0.5 µg) orally once daily during the whole treatment course
Number of subjects: 150

Group type: COMPARATOR
Intervention: AC (control group)
Number of subjects: 150
Study: 34294101

Group type: EXPERIMENTAL
Intervention: Kinyarwanda version of the PAID questionnaire
Number of subjects: 266
Study: 34761610

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (CCRT) after surgery
Number of subjects: 84

Group type: COMPARATOR
Intervention: Adjuvant radiotherapy after surgery
Number of subjects: 84
Study: 32649808

Group type: EXPERIMENTAL
Intervention: Single-step border molding technique using addition vinyl silicone impression material (P-group)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sectional border molding technique using green stick compound (Z-group)
Number of subjects: 10
Study: 34786906

Group type: EXPERIMENTAL
Intervention: Focused extracorporeal shock wave therapy (f-ESWT) on myofascial points
Number of subjects: 30

Group type: COMPARATOR
Intervention: Traditional focused extracorporeal shock wave therapy (ESWT) on the medial calcaneal tubercle
Number of subjects: 30
Study: 33278417

Group type: EXPERIMENTAL
Intervention: MITRACLIP® device
Number of subjects: 14647
Study: 33589725

Group type: EXPERIMENTAL
Intervention: Self-Video (video-assisted self-directed course)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Ins-Video (video-assisted facilitator-led course)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 134
Study: 35442431

Group type: EXPERIMENTAL
Intervention: CBT plus tDCS
Number of subjects: 148

Group type: COMPARATOR
Intervention: CBT alone
Number of subjects: 148

Group type: COMPARATOR
Intervention: CBT plus sham-tDCS
Number of subjects: 148
Study: 33009565

Group type: EXPERIMENTAL
Intervention: Fluoride varnish (1.5% ammonium fluoride) applied every sixth week during orthodontic treatment
Number of subjects: 166

Group type: COMPARATOR
Intervention: Placebo varnish (non-fluoride) applied every sixth week during orthodontic treatment
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Fluoride varnish
Number of subjects: 166

Group type: COMPARATOR
Intervention: Placebo varnish
Number of subjects: 166
Study: 32664177

Group type: EXPERIMENTAL
Intervention: Kinect Exercise Group (N=10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional Exercise Group (N=10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Kinect Exercise Group vs Conventional Exercise Group
Number of subjects: 20
Study: 36264751

Group type: EXPERIMENTAL
Intervention: Prophylactic negative-pressure wound therapy (pNPWT) for 7 days
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Prophylactic negative-pressure wound therapy (pNPWT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (sterile gauze dressing)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 34061146

Group type: EXPERIMENTAL
Intervention: Implantable loop recorder monitoring for 12 months
Number of subjects: 300

Group type: COMPARATOR
Intervention: External loop recorder monitoring for 30 days
Number of subjects: 300
Study: 36103393

Group type: EXPERIMENTAL
Intervention: Local area code
Number of subjects: 685

Group type: COMPARATOR
Intervention: Generic toll-free area code
Number of subjects: 685
Study: 33825304

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.5 µg/g, group D)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Midazolam (0.08 mg/kg, group M)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Normal saline (group C)
Number of subjects: 120
Study: 35309584

Group type: EXPERIMENTAL
Intervention: Active tDCS combined with VNeST
Number of subjects: 6

Group type: COMPARATOR
Intervention: Sham stimulation combined with VNeST
Number of subjects: 6
Study: 32533354

Group type: EXPERIMENTAL
Intervention: SORT maneuver (sniffing position, NGT orientation, contralateral rotation, and twisting movement)
Number of subjects: 396

Group type: COMPARATOR
Intervention: NFLP (neck flexion lateral pressure)
Number of subjects: 396

Group type: COMPARATOR
Intervention: NFLP
Number of subjects: 396
Study: 33454739

Group type: EXPERIMENTAL
Intervention: Placebo analgesia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Opioid antagonist
Number of subjects: 0
Study: 32442480

Group type: EXPERIMENTAL
Intervention: Chronic breathlessness (mMRC scale)
Number of subjects: 2883

Group type: EXPERIMENTAL
Intervention: Chronic breathlessness for two to six years
Number of subjects: 2883

Group type: EXPERIMENTAL
Intervention: Chronic breathlessness attributed to cardiac failure
Number of subjects: 2883

Group type: EXPERIMENTAL
Intervention: Worse chronic breathlessness
Number of subjects: 2883
Study: 33141065

Group type: EXPERIMENTAL
Intervention: Cold water (2.1 ± 0.64 °C)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Room temperature water (19.4 ± 0.5 °C)
Number of subjects: 10
Study: 32484444

Group type: EXPERIMENTAL
Intervention: SMART Connections (intervention)
Number of subjects: 349

Group type: COMPARATOR
Intervention: Standard of care (control)
Number of subjects: 349
Study: 35636620

Group type: EXPERIMENTAL
Intervention: MicroShunt
Number of subjects: 0

Group type: COMPARATOR
Intervention: Trabeculectomy
Number of subjects: 0
Study: 34068594

Group type: EXPERIMENTAL
Intervention: Emotional ability
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Age differences
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Gender differences
Number of subjects: 300
Study: 32661106

Group type: EXPERIMENTAL
Intervention: Euglycemia, low insulin (EuLoI)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Hyperglycemia, low insulin (HyLoI)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Euglycemia, high insulin (EuHiI)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Participants without diabetes
Number of subjects: 12
Study: 34808255

Group type: EXPERIMENTAL
Intervention: Prophylactic gabapentin (600 mg thrice daily)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 33096126

Group type: EXPERIMENTAL
Intervention: Provider training intervention
Number of subjects: 3216
Study: 36284033

Group type: EXPERIMENTAL
Intervention: Ischemia-guided non-culprit vessel angioplasty
Number of subjects: 109

Group type: COMPARATOR
Intervention: Routine non-culprit vessel angioplasty
Number of subjects: 109
Study: 33504042

Group type: EXPERIMENTAL
Intervention: Therapeutic physical exercise (TPE) program supervised by a physiotherapist
Number of subjects: 54
Study: 32822633

Group type: EXPERIMENTAL
Intervention: Atogepant 10 mg once daily
Number of subjects: 825

Group type: EXPERIMENTAL
Intervention: Atogepant 30 mg once daily
Number of subjects: 825

Group type: EXPERIMENTAL
Intervention: Atogepant 60 mg once daily
Number of subjects: 825

Group type: EXPERIMENTAL
Intervention: Atogepant 30 mg twice daily
Number of subjects: 825

Group type: EXPERIMENTAL
Intervention: Atogepant 60 mg twice daily
Number of subjects: 825

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 825
Study: 36149220

Group type: EXPERIMENTAL
Intervention: Toothpaste containing 1450 ppm fluoride and aloe vera
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Toothpaste with sodium monofluorophosphate formulation
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Groups B1 and A2
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Groups A3 and B3
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Group B4
Number of subjects: 72
Study: 34622845

Group type: EXPERIMENTAL
Intervention: A+HA (20 mL supplement mixture containing 50 mg HA, 750 mg glucosamine, and 250 mg chondroitin)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 616994361

Group type: EXPERIMENTAL
Intervention: Education based on health belief model with relaxation
Number of subjects: 120
Study: 34788698

Group type: EXPERIMENTAL
Intervention: Neoadjuvant and concurrent androgen deprivation therapy (ADT) for 6 months starting 4 months before prostate radiation therapy
Number of subjects: 393

Group type: COMPARATOR
Intervention: Concurrent and adjuvant ADT for 6 months starting simultaneously with radiation therapy
Number of subjects: 393
Study: 33895829

Group type: EXPERIMENTAL
Intervention: Height adjustment in multivariable Mendelian randomization (MVMR) analysis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other candidate mediators (free T4, systolic blood pressure, heart rate)
Number of subjects: 0
Study: 35583486

Group type: EXPERIMENTAL
Intervention: Ratanasampil (RNSP)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Flunarizine (FLZ)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 32188492

Group type: EXPERIMENTAL
Intervention: Conventional treatment plus 1g of intravenous calcium gluconate (group 2)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional treatment (morphine 0.1 mg/kg + normal saline; group 1)
Number of subjects: 50
Study: 33272766

Group type: EXPERIMENTAL
Intervention: SELF intervention
Number of subjects: 40

Group type: COMPARATOR
Intervention: Waitlist-control (treatment-as-usual)
Number of subjects: 40
Study: 34921023

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 102

Group type: COMPARATOR
Intervention: Carboplatin-Pemetrexed
Number of subjects: 102
Study: 35613672

Group type: EXPERIMENTAL
Intervention: Targeted hypoglossal nerve stimulation (activated at Month 1)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (activated at Month 7)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Quality of life metrics
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Oximetry metrics
Number of subjects: 150